Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Hits Two More Asian Firms With Drug GMP Warning Letters

Executive Summary

The spate of recent warning letters going to foreign pharmaceutical manufacturers continues as two Asian firms get into trouble for GMP violations: Firson Co. in South Korea and Wuxi Medical Instrument Factory in China.

You may also be interested in...



Lost In Translation: Rx Drug Used Where OTC Hydrocortisone Belongs

In a "translation mistake," Zhanjiang Jimin Pharmaceutical's management "thought hydrocortisone was the same material as dexamethasone," FDA says. The China firm's product, distributed in the US by Lucky Mart Inc. under the brand Piyanping Anti-Itch Lotion, is being recalled.

Lost In Translation: Rx Drug Used Where OTC Hydrocortisone Belongs

In a "translation mistake," Zhanjiang Jimin Pharmaceutical's management "thought hydrocortisone was the same material as dexamethasone," FDA says. The China firm's product, distributed in the US by Lucky Mart Inc. under the brand Piyanping Anti-Itch Lotion, is being recalled.

FDA GMP Warning Letters Review: Rate Soared In 2016 On Sterility And Data Integrity Concerns

Poor data integrity at Asian API firms, poor quality programs at foreign OTC firms and poor sterility assurance at US compounding pharmacies were the main factors leading US FDA to issue 110 drug GMP warning letters in 2016, a huge increase from prior years. Article is first of four-part series in our annual analysis.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS121591

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel